Douglas F. Kling - Dec 29, 2023 Form 3 Insider Report for NewAmsterdam Pharma Co N.V. (NAMS)

Role
Chief Operating Officer
Signature
/s/ Louise Kooij by Power of Attorney for Douglas Kling
Stock symbol
NAMS
Transactions as of
Dec 29, 2023
Transactions value $
$0
Form type
3
Date filed
12/29/2023, 04:30 PM
Next filing
Jan 3, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding NAMS Option (right to buy) Dec 29, 2023 Ordinary Shares 6K $10.90 Direct F1
holding NAMS Option (right to buy) Dec 29, 2023 Ordinary Shares 283K $10.90 Direct F2
holding NAMS Option (right to buy) Dec 29, 2023 Ordinary Shares 663K $10.00 Direct F3
holding NAMS Option (right to buy) Dec 29, 2023 Ordinary Shares 426K Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on January 1, 2023. All shares underlying the option will vest in full on January 1, 2027.
F2 The option was granted on January 1, 2023. 72,303 shares underlying the option vest on January 1, 2024 and 6,026 shares underlying the option will vest on each monthly anniversary thereafter, subject to the Reporting Person's continued service through each such date.
F3 The option was granted on November 22, 2022. The shares underlying the option vest in equal monthly installments over four years, with the first 1/48th of such shares vesting on December 1, 2022 and the remaining installments vesting on each one-month anniversary of the grant date, subject to the Reporting Person's continued service through each such date.
F4 The option was granted on November 22, 2022 to replace an option originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 121,754 of the shares underlying the option immediately vested on the grant date. 25% of the remaining shares underlying the option vested on, March 31, 2022, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.
F5 The exercise price of the option is Euro 1.16392.

Remarks:

Exhibit List: Exhibit 24.1 - Power of Attorney